Bradley Merrill Thompson Quoted in Article, “FDA’s Mobile Medical Apps Guidance: Our Advisors Weigh In”


Bradley Merrill Thompson, a Member of the Firm in the Health Care and Life Sciences practice, in the Washington, DC, office, was quoted in an article titled "FDA's Mobile Medical Apps Guidance: Our Advisors Weigh In."

Following is an excerpt:

While the U.S. Food and Drug Administration unveiled its long-awaited final guidance on the regulation of mobile medical applications on Monday, some in the healthcare industry weren't sure it went far enough. For instance, Bradley Merrill Thompson, who serves as general counsel for the mHealth Regulatory Coalition, said the final guidance was porous in some areas, such as the definition of what are regulated; disease intended uses compared to unregulated, wellness intended uses; and the exact meaning of an accessory to a medical device.